Alnylam Pharmaceuticals (ALNY) reported first-quarter 2025 adjusted loss of 1 cent per share, narrower than the Zacks Consensus Estimate of a loss of 56 cents. The company had incurred a loss of 16 cents per share in the year-ago quarter. The adjusted figure excluded items like stock-based compensation expenses and unrealized loss on marketable equity securities.Alnylam recorded total revenues of $594.2 million in the quarter, which surpassed the Zacks Consensus Estimate of $588.2 million. In the year-ago q ...

First Quarter 2025 Financial Results May 1, 2025 © 2025 Alnylam Pharmaceuticals, Inc. 1 Agenda Welcome • Christine Lindenboom Chief Corporate Communications Officer Overview • Yvonne Greenstreet, M.D., MBA Chief Executive Officer Commercial Highlights • Tolga Tanguler Chief Commercial Officer Pipeline • Pushkal Garg, M.D. Chief Medical Officer Financial Summary and Upcoming Milestones • Jeff Poulton Chief Financial Officer Q&A Session 2 Alnylam Forward Looking Statements This presentation contains forward-l ...

Alnylam Pharmaceuticals (ALNY) Q1 2025 Earnings Call May 01, 2025 08:30 AM ET Speaker0 Good morning, ladies and gentlemen, and welcome to the Alnylam Pharmaceuticals Q1 twenty twenty five Earnings Conference Call. At this time, all lines are in a listen only mode. Following the presentation, we will conduct a question and answer session. This call is being recorded on Thursday, 05/01/2025. I would now like to turn the conference over to Alnylam. Please go ahead. Speaker1 Good morning. I'm Christine Lindenbo ...

Alnylam Pharmaceuticals (ALNY) Q1 2025 Earnings Call May 01, 2025 08:30 AM ET Company Participants Christine Lindenboom - Chief Corporate Communications OfficerYvonne Greenstreet - Chief Executive OfficerTolga Tanguler - Executive VP & Chief Commercial OfficerPushkal Garg - Chief Medical Officer and Executive VP of Development & Medical AffairsJeff Poulton - Chief Financial OfficerGena Wang - MD - Biotech Equity ResearchTeraesa Vitelli - Equity Research AssociateGary Nachman - Managing Director - Equity Res ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________ FORM 10-Q ____________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number 001-36407 ___________________ ...

Wall Street analysts forecast that Alnylam Pharmaceuticals (ALNY) will report quarterly loss of $0.56 per share in its upcoming release, pointing to a year-over-year decline of 250%. It is anticipated that revenues will amount to $588.18 million, exhibiting an increase of 19% compared to the year-ago quarter.The consensus EPS estimate for the quarter has undergone a downward revision of 4.6% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have re ...

The market expects Alnylam Pharmaceuticals (ALNY) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to b ...

Alnylam Pharmaceuticals (ALNY) shares rallied 8.5% in the last trading session to close at $243.27. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 6% loss over the past four weeks.The rise in share price came after President Trump announced a 90-day pause on his sweeping tariffs against non-retaliating countries.This RNA interference drug developer is expected to post quarterly loss of $0.55 per share in its ...

Dublin, March 28, 2025 (GLOBE NEWSWIRE) -- The "Innovation Insights: siRNA gene silencing" report has been added to ResearchAndMarkets.com's offering. In terms of deals, there have been 334 deals totaling US$107 billion in the siRNA gene silencing sector. The United States and Ireland stand out with two major M&A deals worth $54.9 billion. The highest deal volume was observed in 2023, while the highest deal value was seen in 2020. The slight decline in 2021, followed by a slight increase in 2022, may indic ...

The U.S. Food and Drug Administration on Thursday approved Alnylam Pharmaceuticals Inc.'s ALNY supplemental application for Amvuttra (vutrisiran).The drug treats adults with cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis, or ATTR-CM, to reduce cardiovascular mortality, cardiovascular hospitalizations, and urgent heart failure visits.ATTR-CM is a rare heart condition where a protein called transthyretin (TTR) misfolds and deposits in the heart, causing it to stiffen and potentia ...